The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co., Ltd’s GPRC5D-targeted chimeric antigen receptor (CAR)-T cell therapy, OriCAR-017, has been granted approval for clinical trials. The therapy is intended for the treatment of recurrent refractory multiple myeloma (R/R MM).
GPRC5D as a Therapeutic Target for Multiple Myeloma
GPRC5D, a G protein-coupled receptor highly expressed in multiple myeloma cells and less so in normal tissues, presents a promising therapeutic target for multiple myeloma treatments. OriCAR-017 is recognized as China’s first and the world’s second therapy of its kind to enter clinical trials, boasting significant differentiated advantages in development speed, efficacy, and safety.
OriCAR-017’s Global Recognition and Partnerships
OriCAR-017 was awarded orphan drug designation (ODD) in the US in October 2022, highlighting its potential to address unmet medical needs. The study results for R/R MM were published at the ASCO and EHA annual meetings in 2022 and in The Lancet Haematology in January 2023. Oricell has also secured a USD 142 million licensing deal with Antengene Corp., Ltd (HK.6996), allowing Antengene to develop YN051 (ATG101), a PD-L1/4-1BB bispecific antibody currently undergoing regulatory Phase I studies in Australia, the US, and China.-Fineline Info & Tech
